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PCoronary Artery Disease
Randomized, Double-Blinded,
lacebo-Controlled Multicenter Trial
f Adenosine as an Adjunct to Reperfusion in the
reatment of Acute Myocardial Infarction (AMISTAD-II)
llan M. Ross, MD, FACC,* Raymond J. Gibbons, MD, FACC,† Gregg W. Stone, MD, FACC,‡
obert A. Kloner, MD, PHD, FACC,§ R. Wayne Alexander, MD, PHD, FACC, for the
MISTAD-II Investigators
ashington, DC; Rochester, Minnesota; New York, New York; Los Angeles, California; and Atlanta, Georgia
OBJECTIVES The purpose of this research was to determine the effect of intravenous adenosine on clinical
outcomes and infarct size in ST-segment elevation myocardial infarction (STEMI) patients
undergoing reperfusion therapy.
BACKGROUND Previous small studies suggest that adenosine may reduce the size of an evolving infarction.
METHODS Patients (n  2,118) with evolving anterior STEMI receiving thrombolysis or primary
angioplasty were randomized to a 3-h infusion of either adenosine 50 or 70 g/kg/min or of
placebo. The primary end point was new congestive heart failure (CHF) beginning 24 h
after randomization, or the first re-hospitalization for CHF, or death from any cause within
six months. Infarct size was measured in a subset of 243 patients by technetium-99m
sestamibi tomography.
RESULTS There was no difference in the primary end point between placebo (17.9%) and either the
pooled adenosine dose groups (16.3%) or, separately, the 50-g/kg/min dose and 70-g/kg/
min groups (16.5% vs. 16.1%, respectively, p  0.43). The pooled adenosine group trended
toward a smaller median infarct size compared with the placebo group, 17% versus 27% (p 
0.074). A dose-response relationship with final median infarct size was seen: 11% at the high
dose (p  0.023 vs. placebo) and 23% at the low dose (p  NS vs. placebo). Infarct size and
occurrence of a primary end point were significantly related (p  0.001).
CONCLUSIONS Clinical outcomes in patients with STEMI undergoing reperfusion therapy were not
significantly improved with adenosine, although infarct size was reduced with the 70-g/kg/
min adenosine infusion, a finding that correlated with fewer adverse clinical events. A larger
study limited to the 70-g/kg/min dose is, therefore, warranted. (J Am Coll Cardiol 2005;
ublished by Elsevier Inc. doi:10.1016/j.jacc.2005.02.06145:1775–80) © 2005 by the American College of Cardiology Foundation
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linimizing infarct size by restoring flow in the occluded
oronary artery is a central objective of acute therapy for
T-segment elevation myocardial infarction (STEMI). Ex-
erimental evidence suggests that further infarct size limi-
ation might be achieved by use of drugs to limit irrevocable
yocyte necrosis (1). Approaches beneficial in experimental
odels of acute MI include antioxidants to mitigate
eperfusion-associated oxidative stress, rheological agents to
mprove blood viscosity and microvascular perfusion,
xygen-carrying polymers, anti-inflammatory agents, and
trategies to reduce injurious intracellular ion shifts. Clinical
rials using these approaches have been either negative (2–7)
r mixed (with insulin-glucose-potassium, or magnesium
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nstitute of Good Samaritan Hospital, Los Angeles, California; and the Department
f Medicine, Emory University School of Medicine, Atlanta, Georgia.
Manuscript received October 15, 2004; revised manuscript received December 28,
004, accepted February 14, 2005.nfusion, or sodium hydrogen exchange inhibitors) (8–12).
denosine, however, may be an important exception as it
as consistently provided myocardial protection from isch-
mic injury in animal models (13–15) and in small clinical
tudies of STEMI (16–20), myocardial ischemia (21), and
oronary artery bypass surgery (22).
In the Acute Myocardial Infarction Study of Adenosine
AMISTAD-I) of 236 thrombolytic-treated patients, a
ignificant 33% relative reduction in infarct size was seen
ith a 3-h adenosine infusion (70 g/kg/min) compared
ith controls (18). Efficacy, however, was limited to patients
ith anterior infarction, and the trial was underpowered to
valuate clinical benefit. Also, a trend toward an increase in
dverse clinical events was present in patients with nonan-
erior STEMI. The AMISTAD-II trial, therefore, was
esigned as a larger trial of adenosine as adjunctive therapy
o either thrombolytic or mechanical reperfusion in acute
nterior STEMI. Both clinical and infarct size end points
ere evaluated with both the 70-g/kg/min dose and a
ower dose of 50 g/kg/min.
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tudy group. This double-blinded, placebo-controlled,
andomized study was conducted in 13 countries (390 sites)
Appendix), and enrolled 2,118 patients between June 1999
nd December 2000. Enrollment required age over 18 years,
eperfusion therapy (fibrinolysis or percutaneous interven-
ion) within 6 h of onset of ischemic type pain (30 min),
nd electrocardiographic evidence of anterior STEMI.
lectrocardiographic requirements were either 2 mm of
T-segment elevation in at least two contiguous precordial
eads or (presumed) new left bundle branch block. Informed
ritten consent was provided by all patients. Table 1 lists
xclusion criteria.
reatment regimen. Patients selected for reperfusion ther-
py were randomly assigned to adenosine, 70 g/kg/min
the AMISTAD-I dose) or 50 g/kg/min (utilized to
valuate dose-related responses), or to placebo in a 1:1:1
Abbreviations and Acronyms
AMISTAD  Acute Myocardial Infarction Study of
Adenosine
CHF  congestive heart failure
DSMB  Data Safety Monitoring Board
ITT  intention to treat
MI  myocardial infarction
STEMI  ST-segment elevation myocardial
infarction
able 1. Exclusion Criteria
All Patients
1. Initiation of reperfusion therapy (thrombolysis or mechanical
reperfusion) before initiation of study drug
2. MI precipitated by a condition other than atherosclerotic coronary
artery disease (e.g., arrhythmia, severe anemia, hypoxia,
thyrotoxicosis, cocaine, severe valvular disease, hypotension)
3. Systolic blood pressure 90 mm Hg (including cardiogenic shock)
not responsive to intravenous fluids
4. Sustained bradycardia (55 beats/min for 10 min)
5. Clinical evidence of significant reactive airway disease (e.g., asthma)
6. Greater than first-degree AV block without functional pacemaker
7. Received dipyridamole within 24 h of randomization
8. Coexistent condition associated with a limited life expectancy
(e.g., advanced cancer, end-stage pulmonary disease)
9. Participation in another clinical research study involving the
evaluation of another investigational drug or device within 7 days
of randomization
Patients Who Were to Receive Thrombolytic Therapy
as Initial Reperfusion Strategy
0. Active internal bleeding or history of hemorrhagic diathesis
(including heparin-induced thrombocytopenia)
1. Previous hemorrhagic stroke at any time or any stroke within
1 year
2. Major surgery or trauma within the previous 6 weeks
3. Recent non-compressible vascular puncture
4. Severe uncontrolled hypertension (blood pressure 180/110 mm Hg
determined from a reliable measurement before randomizationaV  atrioventricular; MI  myocardial infarction.cheme. Study drug infusion (3 h) had to be started within
5 min either of the start of fibrinolysis or before coronary
ntervention. If severe hypotension, bradycardia, or bron-
hospasm was observed, the infusion rate could be reduced
y decrements of 15%. Aminophylline was permitted for
dverse adenosine responses. Other concomitant therapies
ere permitted at the discretion of the managing physician.
linical end points. The primary clinical efficacy end point
by intention to treat [ITT]) was time from randomization
o first occurrence (24 h after initiating reperfusion) of
n-hospital congestive heart failure (CHF), first re-
ospitalization for CHF, or death from any cause during six
onths’ follow-up. For this and other analyses, the principal
respecified comparison was between placebo and the com-
ined adenosine groups. Secondary analyses included com-
arison of each adenosine dose, separately, versus placebo.
nalysis by “treatment per protocol” was also prespecified,
nd defined as including: study drug infusion started within
5 min of the protocol initiation, at least a full hour’s
nfusion, and receiving not less than half or more than twice
he assigned total dose. Secondary end points included
ll-cause and cardiovascular mortality within six months and
hose specific to the infarct size substudy.
Heart failure was judged to be present if two of the
ollowing criteria were documented: new pulmonary edema
y chest X-ray in the absence of a non-cardiac cause, rales
ver one-third or greater of the lung fields believed to be due
o pulmonary edema, pulmonary capillary wedge pressure
18 mm Hg with cardiac index 2.4 l/min/m2, dyspnea
ith pO2 80 mm Hg or O2 saturation 90% without
nown pre-existing lung disease, and use of loop diuretics to
reat presumed pulmonary congestion.
nfarct size substudy. Infarct size was measured by
echnetium-99m sestamibi single-photon emission com-
uted tomography imaging between 120 and 216 h after
andomization. The raw data were processed at the Nuclear
ore Laboratory (Mayo Clinic Foundation, Rochester,
innesota), which was blinded to treatment. Imaging
quipment and image acquisition for each site were quality-
ontrolled using a cardiac phantom as previously described
23). Infarct size was measured as previously described (24)
nd has been related to: ejection fraction and end-systolic
olume (25,26), fibrosis in explanted hearts and myocardial
iopsies (27,28), ventricular function after revascularization
29,30), mortality (31,32), and clinical outcome (33,34).
tatistical analyses and sample size estimates. The pri-
ary end point comparison used the Gehan-Wilcoxon rank
urvival method and assumed a principal event in 16% of the
lacebo group (10% death and 6% CHF). A sample size of
75 per arm would provide 80% power for detecting a 25%
elative difference between pooled adenosine and placebo.
he total sample size projected was 2,100 patients, and
,118 were enrolled. The Data Safety Monitoring Board
DSMB) (Appendix) was empowered to recommend dis-
ontinuation of one adenosine treatment arm (for futility or
dverse event frequency) and continuation of the trial with
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cheme.
The infarct size substudy sample estimate assumed a
edian infarct size of 30% of the left ventricle in placebo-
reated patients. To detect a 20% reduction with 80% power
ould require 175 patients in each group. Infarct size was
eported as median (25%, 75% interquartile ranges) and
ompared by using a model of analysis of covariance on
anks, adjusted for time to therapy and prior history of
nfarction. Significance for all comparisons was set at the
.05 level.
ESULTS
aseline characteristics and therapy were balanced across
he groups (Table 2). The DSMB performed an interim
valuation on the data from 1,010 patients and informed the
teering Committee that the lower dose treatment arm,
owever, would meet futility criteria. Closure of the low-
ose treatment arm would have entailed a statistical penalty.
urthermore, by the time protocol changes could have been
mplemented, over 75% of the projected enrollment would
ave been completed. Funding was not available to support
he increase in sample size that would have been required to
aintain the power of the study. The trial was, therefore,
ompleted with both treatment arms.
linical end points. As analyzed by ITT, the primary end
oint of survival in the absence of in-hospital CHF or
ehospitalization for CHF was 82% in the placebo group,
Table 2. Patient Demographics by Treatment
Characteristic Placebo
n 703
Age (yrs) 60  13
Males (%) 73.5
Weight (kg) 78  15
Height (cm) 170  9
Time, symptom onset to
treatment (min)
200  85
Diabetes mellitus (%) 15.9
Previous myocardial infarction (%) 11.7
Killip class
I 85.2
II 12.9
III 1.7
IV 0.1
Index reperfusion therapy
Thrombolysis 58.5
tPA 11.5
Streptokinase 42.5
Other 4.4
Angioplasty 39.8
Therapy within 48 h
ACE inhibitors 65.3
Beta-blockers 86.3
Statins 24.9
Aldosterone antagonists 1.9
ACE  angiotensin-converting enzyme; tPA  tissue plasmnd 84% in the pooled adenosine groups (p  0.43). inalyzed on a “per protocol” basis, survival free of in-hospital
HF or rehospitalization for CHF was 82% in the placebo
roup and 85% in the pooled adenosine group. This 17% risk
eduction also was not statistically significant (p  0.16).
When the individual adenosine dose groups were ana-
yzed on an ITT basis, there were no significant differences
mong the placebo, 50-g, and 70-g treatment groups.
ortality occurred in 11.8% of placebo patients versus
0.4% in the 50-g group (p  0.37) and in 10.2% of the
0-g group (p  0.31 vs. placebo). The specific frequency
f the components of the principal end points by both ITT
nd per protocol are summarized in Table 3.
nfarct size substudy. A total of 266 patients were enrolled
n the imaging substudy. Of these, 254 actually underwent
maging, and 243 (91% of those enrolled) had images
uitable for quantitative analysis. Figures 1 and 2 display
nfarct size (% left ventricle). In the placebo group, the
edian infarct size was 27% (interquartile range 4% to
9%). In the pooled adenosine group, the median infarct
ize tended to be reduced to 17% (1% to 39%), p  0.074.
edian infarct size in the 50-g/kg/min adenosine group
as 23% (6% to 39%), not significantly different from
lacebo (p  0.41). In contrast, median infarct size in the
0-g/kg/min group was 11% (0% to 37%), representing a
ignificant reduction from that in the placebo group (p 
.023).
There was also a significant association between infarct
ize and the development of in-hospital CHF, rehospital-
p
Adenosine
50 g/kg/min
Adenosine
70 g/kg/min p Value
702 713
60  13 61  13 NS
74.2 72.7 NS
79  15 80  15 NS
170  9 171  9 NS
198  86 195  84 NS
16.4 17.0 NS
15.1 11.9 NS
83.4 83.6
14.7 13.9 NS
1.6 1.8
0.3 0.7
58.1 58.3
11.6 10.9
43.8 43.6 NS
2.7 3.8
41.1 39.7
67.4 69.4 NS
82.3 82.1 NS
23.5 22.8 NS
2.4 3.3 NS
n activator.Grouzation for CHF, or death. The median infarct size in the 28
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26% to 53%), significantly larger than the 17% (1% to 39%)
n the 215 patients without any of these end points (p 
.001) (Fig. 2).
dverse clinical events. Adenosine infusion at either dose
as associated with a low incidence of adverse clinical events
elative to placebo (Table 4). There was a modest increase in
denosine-associated hypotension, which was generally well
olerated. Recurrent MI was observed in 2% of patients in
ach treatment group, and total cerebrovascular accidents
ccurred in 1% of each group.
ISCUSSION
n the present trial, intravenous adenosine as an adjunct to
eperfusion therapy in acute anterior STEMI did not result
n an overall reduction in adverse clinical events, although
he study medication was well tolerated and resulted in a
ose-related reduction in infarct size. The reduction in
igure 1. Infarct size measured as a percent of the left ventricle (LV) by
echnetium-99m single-photon emission computed tomographic imaging
n the 243 patients in the infarct size substudy with images suitable for
uantitation. The 25th percentile, median, and 75th percentiles are shown
or the placebo group, the pooled adenosine group, the 50-g/kg/min
denosine group, and the 70-g/kg/min adenosine group. Only the higher
Table 3. Primary Clinical End Points
End Point Placebo
P
Ad
Intention-to-treat analysis
n 703
Death 83 (11.8%) 146
In-hospital CHF 28 (4.0%) 60
Re-hospitalization for CHF 30 (4.3%) 56
Composite 126 (17.9%) 231
Per protocol analysis
n 538
Death 62 (11.5%) 99
In-hospital CHF 25 (4.6%) 44
Re-hospitalization for CHF 25 (4.6%) 39
Composite 98 (18.2%) 160
*One randomized patient was administratively excluded beca
information is available; †placebo vs. pooled adenosine.
CHF  congestive heart failure.denosine dose group showed a significant reduction in median infarct size
elative to placebo (p  0.023)
s
infarct size in the 70-g/kg/min dose group seen in this trial
s consistent with the first AMISTAD trial in which this
ose was used (18). In the current trial, the median infarct
ize in the 70-g/kg/min group (11% of the left ventricle)
epresented a 57% relative reduction from the placebo group
edian (26%). In AMISTAD-I, the median infarct size in
he treated group with anterior STEMI was 15% versus
5% with placebo (a relative reduction of 67%). Thus, these
wo trials support the contention that a 3-h 70-g/kg/min
denosine infusion reduces infarct size in patients with
nterior STEMI undergoing reperfusion therapy.
Despite the fact that a strong relationship was present
etween infarct size and the primary clinical end point
death or heart failure), only a weak trend was present
oward improvement in clinical outcomes with the pooled
denosine dose regimens. A likely explanation for failure of
he trial to demonstrate a clinical benefit was that it was
nderpowered. The sample size calculation was based on a
eduction of events in the pooled adenosine group by 25%
ompared with placebo. The reduction observed was only
igure 2. Infarct size measured as a percent of the left ventricle (LV) by
echnetium-99m single-photon emission computed tomographic sestamibi
maging in the 28 patients in the infarct size substudy who suffered a
rimary end point (death, in-hospital congestive heart failure [CHF], or
e-hospitalization for CHF), compared with the 215 patients who did not
ave an end point. The 25th percentile, median, and 75th percentiles are
reatment Groups
p
Value†
d
ine
Adenosine*
50 g/kg/min
Adenosine
70 g/kg/min
701 713
3%) 73 (10.4%) 73 (10.2%) 0.29
%) 28 (4.0%) 32 (4.5%) 0.75
%) 27 (3.9%) 29 (4.1%) 0.81
3%) 116 (16.5%) 115 (16.1%) 0.43
519 531
%) 45 (8.7%) 54 (10.2%) 0.18
%) 22 (4.2%) 22 (4.1%) 0.70
%) 21 (4.0%) 18 (3.3%) 0.45
2%) 79 (15.2%) 81 (15.2%) 0.16
subject was noted to have been incarcerated and no furtherT
oole
enos
1,414
(10.
(4.2
(4.0
(16.
1,050
(9.4
(4.2
(3.7
(15.
use thehown for each group. The group with a primary end point had larger
nfarcts than did those without (p  0.001).
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June 7, 2005:1775–80 Adenosine in the Treatment of AMI (AMISTAD-II)1%. This result in part reflects the modest infarct size
eduction in the 50% of patients receiving the lower aden-
sine dose. There were two reasons for evaluating the lower
ose in the present study: a preclinical study had suggested
hat both low and high doses were equally effective in
educing myocardial infarct size (35), and there was interest
n determining if a lower (but effective) dose would further
educe the incidence of bradycardia and hypotension. More-
ver, neither adenosine group alone was of sufficient size to
ake a statistically robust and informative comparison to
he placebo group regarding the clinical end point.
As noted, there is a strong body of data from animal
odels of MI indicating that adenosine and adenosine
gonists are myocardial protectants (14,15,36–39). The
umerous potential mechanisms have recently been re-
iewed (40). Although it is known that stimulation of
denosine receptors mimics ischemic preconditioning (15),
t is unlikely that this mechanism played a role in the present
tudy, because adenosine was not administered until after
oronary artery occlusion. Adenosine has anti-inflammatory
ffects that may inhibit neutrophil adhesion to endothelium
nd migration into the myocardium, cytokine release from
ononuclear cells, release of oxygen radicals, and cardio-
yocyte apoptosis (40). Adenosine also has an anti-platelet
ffect (41) that may have a role in maintaining infarct artery
atency.
Previously, as noted, there has been no consistent clinical
vidence that a pharmacologic agent, administered as an
djunct to reperfusion, can actually impact infarct size (1).
ow, both AMISTAD-I (18) and AMISTAD-II have
hown that adenosine reduces infarct size. These data are
lso consistent with the results of a small trial of intracoro-
ary infusion of adenosine in patients with acute MI
ndergoing primary angioplasty (17).
tudy limitations. The major limitation of this study was
hat the sample size was too small to confirm that the
bserved adenosine-related reduction in the combined clin-
cal end point was statistically significant.
onclusions. This trial adds to previous evidence that a
-h adenosine infusion at 70 g/kg/min (but not at the
ower 50-g/kg/min dose) reduces infarct size in anterior
I patients when given in conjunction with reperfusion
herapy. The correlation between infarct size and clinical
Table 4. Adverse Events by Treatment Group
Plac
n 692
Hypotension (%) 14
Bradycardia (%) 2
Ventricular tachycardia (%) 3
Second-degree AV block (%) 0
Third-degree AV block (%) 0
Nausea/vomiting (%) 6
Premature drug discontinuation (%) 3
AV  atrioventricular.utcome in this study, as well as the trend toward improvedlinical outcomes, suggests that a more robustly powered
nvestigation of this relatively safe and inexpensive drug as
djunctive therapy to reperfusion is warranted to demon-
trate whether the reduced infarct size achieved with the
igher infusion dose translates into enhanced event-free
urvival.
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